GCG and diabetes mellitus: Literature data report that GLP-1 analogs improve the striatal dopamine level in patients with Parkinson’s disease and diabetes [62], protect the dopaminergic neurons in the substantia nigra and prevent dopamine loss in basal ganglia retaining control of motor functions [63,64,65].